Jonathan S. Katz, MD, is the Director, Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California. He received his BA from The Johns Hopkins University and his medical degree from Tulane University School of Medicine. He subsequently completed his neurology training at the University of Washington and neuromuscular diseases at the University of Texas, Southwestern Medical Center.
Dr. Katz is board certified in in Psychiatry and Neurology and specializes in the management and treatment of neuromuscular diseases such as CIDP, GBS, ALS, myasthenia gravis and multifocal motor neuropathy. He also sits on the medical advisory board of the Guillain-Barre CIDP Foundation International, California State Myasthenia Gravis Association and Myasthenia Gravis Association of America. He has authored over 80 publications, written 7 text book chapters and has participated in more than 23 Investigator Initiated Studies over the past 10 years, and has been national PI in several ALS trials. Notably among his many contributions, Dr. Katz has been the first author of several pioneering clinical papers that have focused on novel presentations which have become part of the neurological nomenclature including distal acquired demyelinating sensory polyneuorpathy (DADS), isolated neck extensor myopathy (INEM), multifocal acquired motor axonopathy (MAMA), and brachial amyotrophic diplegia (BAD).
Dr. Hans Katzberg is a neuromuscular specialist and clinical investigator at the University Health Network / Toronto General Hospital and has been on faculty at the University of Toronto as Assistant Professor of Neurology. He obtained his undergraduate and medical degrees at the University of British Columbia and did his residency in neurology at the University of Toronto where he was chief resident from 2006-7. He later completed fellowships in neuromuscular medicine and neurophysiology (EMG) at Stanford University, where he also obtained a MasterÔÇÖs degree in clinical epidemiology.
He has been on staff at the Ellen and Martin Prosserman Center for Neuromuscular Diseases at TGH since 2010, where he runs neuromuscular and EMG clinics, is active in training of neurology and physiatry residents / fellows and conducts clinical research. He is cross-appointed to Sick Kids Hospital where he coordinates a transition clinic for young adults with neuromuscular conditions. In 2014 he took over as fellowship program director at the University of Toronto for the Division of Neurology. He is Associate Editor for the Canadian Journal of Neurological Science and co-chair for research in the Canadian Neuromuscular Disease Network. He has a research focus in outcome measures and clinical trials in immune mediated neuromuscular junction disorders such as myasthenia gravis and neuropathies such as CIDP.
Hear the results of a trial to determine the feasibility of switching patients with multifocal motor neuropathy on intravenous to subcutaneous immunoglobulin.
Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program. He is Director of the GBS-CIDP Foundation Center of Excellence at Cedars-Sinai. Prior to his move to California in 2013, he was Associate Chair of Neurology at Wayne State University where he had been for 19 years.
He has been on the Board of Directors of the Peripheral Nerve Society, and on the Steering Committee of the Inflammatory Neuropathy Consortium. He is on the Medical Advisory Boards of the GBS-CIDP Foundation and the Myasthenia Gravis Foundation. He has been involved as an investigator, steering committee member and DSMB member in clinical trials in a number of immune mediated disorders including CIDP, myasthenia gravis and multifocal motor neuropathy.
Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.
Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring. He completed his medical training at the University of Casablanca in Morocco. He also has a Master of Biomedical and Physical Engineering of Health in the University of Saints-P├¿res, Paris, and Biostatistics for the Health and Biological Sciences in Pierre at Marie Curie University in Paris. Before joining the pharmaceutical industry he spent 3 years in Emergency department. He gained over 10 years of industry experience in Medical Affairs departments first in central nervous system and psychiatry and then, from 2010 he joined CSL Behring as a medical manager in immunology.
Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.
Claudia Sommer is a Professor of Neurology at the University of W├╝rzburg, Germany. She received training in psychiatry, neuropathology, experimental anesthesia, and neurology. At the University of W├╝rzburg she serves as a consultant in neurology, organizes an outpatient clinic for patients with pain, and leads the Peripheral Nerve Laboratory. Professor SommerÔÇÖs research interests include: the role of cytokines in the pathophysiology of pain, improvement and standardization of diagnostics in neuropathies, and the pathophysiology of antibody-mediated diseases. She has written more than 150 original research papers and more than 100 reviews and book chapters, and has edited several books.
Professor Sommer is active in the development of national and international guidelines on treatment of peripheral neuropathies, nerve and skin biopsies, and treatment of fibromyalgia and neuropathic and facial pain. She is a reviewer for scientific journals and the German Research Foundation (DFG), and serves on the editorial boards of several scientific journals.
Discover the results of two recent clinical studies of IVIg treatments for CIDP.